{
    "clinical_study": {
        "@rank": "148095", 
        "brief_summary": {
            "textblock": "This is a randomized, open controlled multicenter phase II clinical study. The SPSS\n      statistical software estimation of sample size, selection of the initial treatment of\n      locally advanced head and neck squamous cell carcinoma in 120 patients, such as to achieve\n      the desired results, considering expanding the clinical, according to the proportion of 1:1\n      were randomly divided into two groups, all patients were taken, docetaxel + cisplatin 2\n      cycles of induction chemotherapy \u3001Concurrent chemoradiotherapy\uff08tomotherapy+cisplatin\uff09, The\n      experimental group was added with AVASTIN."
        }, 
        "brief_title": "After Induction Chemotherapy of DP Plus DDP Concurrent Radiotherapy With and Without Bevacizumab Study", 
        "completion_date": {
            "#text": "August 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Head and Neck Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Men and women are not limited, requirements of ECOG0-2, age 18-70 years old, pathological\n        stage III (NCCN2012), had not received radiotherapy and chemotherapy, expected to survive\n        more than 3 months, the routine testing, were in the normal range, signed the informed\n        consent\n\n        Exclusion Criteria:\n\n        Do not meet the above criteria; allergic to docetaxel and AVASTIN, or metabolic disorders;\n        associated with gastrointestinal bleeding, perforation and other serious diseases; severe\n        liver disease, kidney disease, respiratory disease or unable to control diabetes,\n        hypertension and other chronic disease; heart disease clinical symptoms; there is\n        peripheral nervous system disorders or have obvious mental disorder and disorders of the\n        central nervous system; active phase >CTCAE2 clinical severe infection; a history of organ\n        transplantation (including bone marrow transplantation of autologous peripheral stem cell\n        transplantation); pregnant, lactating women, women of childbearing age and spouse refused\n        to take effective means of contraception contraception; no legal capacity, continue to\n        influence medical or ethical reasons for who"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with pathological diagnosis of head and neck squamous cell carcinoma"
            }
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047487", 
            "org_study_id": "S2013-110-02"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100853"
                    }, 
                    "name": "PLAGH"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "PLA307"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "Docetaxel (T), Cisplatin (P) After Induction Chemotherapy With and Without Cisplatin (P) Concurrent Radiotherapy (X) Plus Bevacizumab (B) Phase II Clinical Study", 
        "overall_contact": {
            "email": "zhifei115@sohu.com", 
            "last_name": "z f zhao, master", 
            "phone": "13301253566"
        }, 
        "overall_official": {
            "affiliation": "Haidian District Fuxing Road, Beijing No. 28 Department of radiotherapy", 
            "last_name": "j x li, doctor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "ORR", 
            "safety_issue": "No", 
            "time_frame": "three month after ratiotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047487"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese PLA General Hospital", 
            "investigator_full_name": "zhifei zhao", 
            "investigator_title": "resident physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Chinese PLA General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese PLA General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "January 2014"
    }
}